Processes for the preparation of linezolid intermediate

Details Processes for the preparation of linezolid intermediate Processes for the preparation of linezolid intermediate

2007-11-06

2007-11-06

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

11361457

ABSTRACT:
The present invention provides improved methods of converting R—N-(4-morpholiyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) to the intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) that involve the production of fewer by-products than previous methods. The amine (II) may then be converted into linezolid (I) of high chemical purity with respect to the inactive R-enantiomer and bis-linezolid (IV), and is in high yield, without the need for tedious, complicated purification steps, such as chromatography.

REFERENCES:
patent: 4705799 (1987-11-01), Gregory
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 6333198 (2001-12-01), Edmeades et al.
patent: 6444813 (2002-09-01), Bergren
patent: 6559305 (2003-05-01), Bergren
patent: 2001100437 (2001-11-01), None
patent: 2 168 560 (2001-08-01), None
patent: 0 311 090 (1989-04-01), None
patent: 0 352 781 (1990-01-01), None
patent: 0 717 738 (1999-10-01), None
patent: 0 963 980 (1999-12-01), None
patent: WO 93/09103 (1993-05-01), None
patent: WO 95/07271 (1995-03-01), None
patent: WO 01/57035 (2001-08-01), None
patent: WO 03/093247 (2003-11-01), None
patent: WO 2004/026848 (2004-04-01), None
patent: WO 2005/035530 (2005-04-01), None
Brickner, et al., “Synthesis And Antibacterial Activity Of U-100592 And U-100766, Two Oxazolidinone Antibacterial Agents For The Potential Treatment Of Multidrug-Resistant Gram-Positive Bacterial Infections”,Journal of Medicinal Chemistry, vol. 39, No. 3, pp. 673-679, (1996).
Reddy, et al. “Isolation and Characterization of Process-Related Impurities in Linezolid”Journal of Pharmaceutical and Biomedical Analysis, vol. 30, pp. 635-642 (2002).
Perrault, et al., “The Synthesis Of N-Aryl-5(S)-Aminoethyl-2-Oxazolidinone Antibacterials And Derivatives In One Step From Aryl Carbamates”,Organic Process Research&Development, vol. 7, No. 4., pp. 533-546 (2003).
Peng, et al. “Determination of Linezolid In Plasma by Reversed-Phase High-Performance Liquid Chromatography”Journal of Pharmaceutical and Biomedical Analysis, vol. 20, pp. 65-73 (1999).
Gregory, et al. “Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-Oxooxazolidines. 2. The “A” Group.”Journal of Medicinal Chemistry, vol. 33, No. 9, pp. 2569-2578 (1990).
Gregory, et al. “Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-Oxooxazolidines. 1. The “B” Group.”Journal of Medicinal Chemistry, vol. 32, No. 8, pp. 1673-1681 (1989).
Sbardella, et al. “Synthesis and In Vitro Antimycobacterial Activity of Novel 3-(1H-Pyrrol-1-yl)-2-Oxazolidinone Analogues of PNU-100480”Bioorganic&Medicinal Chemistry Letters, vol. 14, pp. 1537-1541 (2004).
Emea—European Medicines Agency “ICH Topic Q 3 A (R1)—Impurities in new Drug Substances” CPMP/ICH/2737/99 (2002).
Emea—European Medicines Agency “ICH Topic Q 2 (R1)—Validation of Analytical Procedures: Text and Methodology” CPMP/ICH/381/95 (1995).
Sheradsky “Azides as Synthetic Starting Materials”The Chemistry of The Azido Group(Ed. S. Patai) Interscience Publishers, Chapter 6, pp. 331-395 (1971).
Merck Index, 13th Edition, Monograph No. 5526, CAS Registry No. 165800-03-3, pp. 986, (2001).
Snyder, et al.,Introduction To Modern Liquid Chromatography, 2ndEd., pp. 549-572, John Wiley & Sons, Inc. (1979).
Strobel, et al.,Chemical Instrumentation: A Systematic Approach, 3rdEd., pp. 391-393, 879-894, 922-952, 953, (1989).
Brittain (Ed.)Polymorphism in Pharmaceutical Solids, Drugs and the Pharmaceutical Sciences vol. 95, pp. 1-2, 178-179, 236, Marcel Dekker, Inc. New York, New York, (1999).
Grant “Theory and Origin of Polymorphism”Polymorphism in Pharmaceutical Solids, Drugs and the Pharmaceutical Sciencesvol. 95 (Ed. Brittain), Marcel Dekker, Inc., pp. 1-33, (1999).
Guillory “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids”Polymorphism in Pharmaceutical Solids, Drugs and the Pharmaceutical Sciencesvol. 95 (Ed. Brittain), Marcel Dekker, Inc., pp. 183-226, (1999).
Byrn, et al.,Solid-State Chemistry Of Drugs, 2ndEd., p. 4, (1999).
Perry's Chemical Engineers' Handbook, 6thEd., pp. 20-54 to 20-57, (1984).
Rouhi, “The Right Stuff”,Chemical&Engineering News, pp. 32-35, (2003).
US Pharmacopia # 23, National Formulary # 18, pp. 1843-1844, (1995).

Affiliated with

Also associated with

Rating

Processes for the preparation of linezolid intermediate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Processes for the preparation of linezolid intermediate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for the preparation of linezolid intermediate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3859212